[
  {
    "ts": null,
    "headline": "What Analysts Are Saying About Labcorp Hldgs Stock",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=ccfea81d7ee5a55a14e2e733e7baba1c088f5a0f97f05d70088b6e3f8f8d8227",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771941656,
      "headline": "What Analysts Are Saying About Labcorp Hldgs Stock",
      "id": 139209911,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/analyst_ratings_3.jpg?width=2048&height=1536",
      "related": "LH",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=ccfea81d7ee5a55a14e2e733e7baba1c088f5a0f97f05d70088b6e3f8f8d8227"
    }
  },
  {
    "ts": null,
    "headline": "Piper Sandler Maintains Neutral on Labcorp Hldgs, Raises Price Target to $300",
    "summary": "Piper Sandler  analyst David Westenberg   maintains Labcorp Hldgs (NYSE:LH) with a Neutral and raises the price target from $270 to $300.",
    "url": "https://finnhub.io/api/news?id=6a36a752ebac037747e36df4e6def69f8ecf301ea22e4de5e9725fe07786c62b",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771936313,
      "headline": "Piper Sandler Maintains Neutral on Labcorp Hldgs, Raises Price Target to $300",
      "id": 139209912,
      "image": "",
      "related": "LH",
      "source": "Benzinga",
      "summary": "Piper Sandler  analyst David Westenberg   maintains Labcorp Hldgs (NYSE:LH) with a Neutral and raises the price target from $270 to $300.",
      "url": "https://finnhub.io/api/news?id=6a36a752ebac037747e36df4e6def69f8ecf301ea22e4de5e9725fe07786c62b"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From Labcorp’s Q4 Earnings Call",
    "summary": "Labcorp’s Q4 results came in below Wall Street’s revenue expectations, leading to a negative market reaction, while management attributed performance to strength in specialty testing and expanded partnerships with hospitals and regional labs. CEO Adam Schechter highlighted the company’s double-digit growth in esoteric testing and the successful integration of recent acquisitions, including Invitae and assets from various health systems. Schechter also acknowledged that lower organic volume growt",
    "url": "https://finnhub.io/api/news?id=4ac2dbd82d7840f1fb5990885a85ad86276b6f99fb13de52f735be21de5932d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771911192,
      "headline": "The 5 Most Interesting Analyst Questions From Labcorp’s Q4 Earnings Call",
      "id": 139193392,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Labcorp’s Q4 results came in below Wall Street’s revenue expectations, leading to a negative market reaction, while management attributed performance to strength in specialty testing and expanded partnerships with hospitals and regional labs. CEO Adam Schechter highlighted the company’s double-digit growth in esoteric testing and the successful integration of recent acquisitions, including Invitae and assets from various health systems. Schechter also acknowledged that lower organic volume growt",
      "url": "https://finnhub.io/api/news?id=4ac2dbd82d7840f1fb5990885a85ad86276b6f99fb13de52f735be21de5932d3"
    }
  }
]